Sam Brusco, Associate Editor08.16.22
BD (Becton, Dickinson and Company) has begun an agreement with rapid, microbiology in-vitro diagnostics firm Accelerate Diagnostics whereby BD will offer Accelerate’s rapid antibiotic resistance and susceptibility testing.
BD will market the Accelerate Pheno system and Accelerate Arc module and test kits via its global network in area where the products have regulatory approval or registration.
The solutions complement BD’s clinical microbiology portfolio and offer results in hours, as opposed to one to two days with some traditional lab methods.
"When a patient is very sick, every minute matters," Brooke Story, president of Integrated Diagnostic Solutions for BD, told the press. "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one. Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance."
Accelerate’s PhenoTest BC kit is FDA-cleared for rapid identification and phenotypic antibiotic susceptibility results in hours from positive blood cultures. Using the test can help optimize antibiotic selection and dosage specific to patients days earlier than traditional methods, according to the company.
The Accelerate Arc module is a load-and-go system that eliminates the need for a subculture for MALDI ID as well as lengthy hands-on time by automating the direct MALDI ID workflow. It’s currently U.S., CE-IVDR and UKCA registered for positive blood cultures.
"With BD's large installed customer base of clinical microbiology systems, this collaboration exponentially increases our global commercial reach and provides numerous ways to increase our market penetration with Pheno and Arc to reach more clinicians and patients," said Jack Phillips, president and CEO of Accelerate Diagnostics. "Beyond the immediate clinical and commercial benefits, we are excited about the opportunity to collaborate with BD as a long-term leader in clinical microbiology."
BD will market the Accelerate Pheno system and Accelerate Arc module and test kits via its global network in area where the products have regulatory approval or registration.
The solutions complement BD’s clinical microbiology portfolio and offer results in hours, as opposed to one to two days with some traditional lab methods.
"When a patient is very sick, every minute matters," Brooke Story, president of Integrated Diagnostic Solutions for BD, told the press. "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one. Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance."
Accelerate’s PhenoTest BC kit is FDA-cleared for rapid identification and phenotypic antibiotic susceptibility results in hours from positive blood cultures. Using the test can help optimize antibiotic selection and dosage specific to patients days earlier than traditional methods, according to the company.
The Accelerate Arc module is a load-and-go system that eliminates the need for a subculture for MALDI ID as well as lengthy hands-on time by automating the direct MALDI ID workflow. It’s currently U.S., CE-IVDR and UKCA registered for positive blood cultures.
"With BD's large installed customer base of clinical microbiology systems, this collaboration exponentially increases our global commercial reach and provides numerous ways to increase our market penetration with Pheno and Arc to reach more clinicians and patients," said Jack Phillips, president and CEO of Accelerate Diagnostics. "Beyond the immediate clinical and commercial benefits, we are excited about the opportunity to collaborate with BD as a long-term leader in clinical microbiology."